Viral loads (& age but not symptoms) influences transmission probability, incubation period & symptomatic/asymptomatic outcome.
Fantastic new study @dr_michaelmarks. Tons to learn & haven't seen any detailed thread yet, so here's one. thelancet.com/journals/lanin…
Background
We know that transmission of SARS-CoV-2 is highly heterogeneous, with most cases infecting no one & minority of cases infecting 1 to many. How much of this is due to variation in infectiousness vs... @_akiraendo@AdamJKucharski@sbfnk@seabbs doi.org/10.12688/wellc…
differences in # & type of contacts including setting & activity (indoors, singing, temp/RH, etc.), & susceptibility of contacts? We have evidence that all of these things likely matter, but evidence linking viral loads of index patient to infection of their contacts was missing.
Why does this matter? Lots of reasons. A few key ones:
If viral loads predicts transmission, then:
-vaccines that reduce viral loads will likely reduce transmission
-individual traits that influence viral loads would also influence transmission
-we can map loads to infectiousness
Methods
This study (part of RCT on hydrox. reducing transmsission) took swabs from symptomatic people (median 4d since onset), measured viral loads & followed contacts for infection/disease w/ repeated swabs & symptom monitoring.
Results
- (left fig) Only 32% of index cases w/ 1+ contact transmitted to 1-5 contacts.
- (right fig) Prob trans inc. w/ viral load of index case from 12% to 24% (but I would like to see more than 3 bins of loads; is pattern linear? asymptomatic? sigmoid?)
Prob transmission increased w/ age of index & contact, household (vs healthcare/nursing home) contact (likely duration higher) but NOT w/ symptoms (cough, runny nose) or mask use by contact.
Interestingly, viral load was higher for index patients w/ cough, fever, loss of smell, runny nose (some on edge of significance but 0.05 is arbitrary & P = 0.019 & 0.087 aren't that different), but not difficult breathing (dyspnoea).
Despite this, as noted above, symptoms (& mask) didn't influence transmission, either in univariate or multivariate analysis. This contrasts w/ another study suggesting cough influenced transmission: academic.oup.com/cid/article/71…
Initial viral loads of contacts influenced whether they went on to develop symptoms & incub period. Not clear if this was b/c some contacts were tested later in infection & had more time to develop higher loads & shorter subsequent incub period (exact time of infection not known)
Viral load of index patient was not strongly correlated w/ load in infected contacts (paper says P=0.10 but relationship looks weaker than that; full stats of analysis not given).
Bonus result: Fraction of contacts that never became symptomatic w/in 14d was only 56% (230/429). Not sure why, but this is very high compared to similar studies in meta-analysis by @nicolamlow@dianacarbg
Ideas? journals.plos.org/plosmedicine/a…
Big Conclusions
-Viral loads in index patients, even 4d post onset are predictor of actual infectiousness. This has long been discussed in context of interpreting viral loads vs age, infectiousness & other patterns. @angie_rasmussen@apsmunro@DrZoeHyde@michaelmina_lab
To make use of this relationship quantitatively would require raw data to re-analyze (see above) & we'd need to map viral loads into common unit from diff studies (no easy matter for many of us who have tried this). @michaelmina_lab@MackayIM@bennyborremans
Regardless, it means viral load values have value in assessing infectiousness & could be used to assess effects of vaccination in reducing infectiousness (with caveats above). Unfortunately these data haven't been presented yet (link if I missed them):
Additional analyses needed: does index patient viral load predict Y/N symptomatic illness in contact? Not analyzed directly, but lack of relationship b/w loads of index & contact & link b/w contact loads & symptoms suggests no.
This would mean that shedding from index case influences prob of infection in contact but that other traits/factors determine subsequent viral dynamics/loads & symptom development in infected contacts.
It is now possible to determine relative importance of infectiousness & # contacts in determining secondary infections using data on # of household & other contacts w/ assumptions about contact types in this study (health care & nursing homes) & others.
Novavax has shared prelim efficacy data by press release: ir.novavax.com/news-releases/…
90% overall, 50% in S Africa (60%) in HIV-.
But there's more...
@carlzimmer has written a nice story about it here:
Article makes very provocative statement - that previous exposure doesn't protect against new variant B.1.351 found initially in S africa. But where are data to support this?
Press release is vague on this. It just says this.
Hundreds of nursing home residents are dying each day due to slow vaccine rollout in SNFs.
CDC vaccine tracking page shows this huge failure.
We are failing to vaccinate the population where most deaths have occurred: nursing homes.
Thread covid.cdc.gov/covid-data-tra…
As most know, ~40% of all deaths in US (& other countries like UK) have been in nursing homes. kff.org/policy-watch/c…
As a result, nursing home residents were put, w/ health care workers (HCW), in top priority tier for vaccination. Great! But allocating vaccines to this group did NOT magically result in shots in arms. That requires huge logistical plan. Unfortunately that plan has not gone well.
New SARS-CoV-2 variant will outrun best control US states achieved in 2020.
W/out rapid action we'll lose race b/w vaccination & virus by much more than we are now.
Much faster vaccine rollout & spacing doses as UK is doing is urgently needed.
Thread.
Background
New variant of SARS-CoV-2 was detected in UK in Sept & spread rapidly since. Estimates suggest it is more transmissible with reproductive number R (# of cases/case) ~50% higher (see tweets in thread for details)
Will vaccination reduce transmission or just disease?
Do 3 vaccines w interim or final phase 3 results (Pfizer, Astrazeneca, Moderna) reduce asymptomatic infections & does reduced symptomatic infection imply reduced infections?
Thread
Background
Developing a vaccine for COVID-19 has been a goal since the virus was 1st identified in Jan 2020.
But what is the purpose of vaccines? Many, it turns out!
They can reduce disease, reduce infection, or reduce infectiousness, or some combination. nymag.com/intelligencer/…
Why does it matter whether vaccine reduces disease, infection or infectiousness?
Because it changes who we vaccinate first & whether vaccination protects friends & family of vaccinated person (herd immunity!).
Why do we exclude groups from vaccine trials (pregnant, lactating women, people w/ anaphylactic reactions) & then allow vaccination of them based on trials? Isn't this recipe for possibly very bad outcomes? Urgent remedy needed.
Thread nytimes.com/2020/12/11/hea…
Pfizer/BioNtech vaccine was just granted EUA from FDA. EUA does not exclude any groups, except children under 16. fda.gov/media/144412/d…
CDC met today & also recommended vaccination w/out clear exclusions for groups excluded (e.g. pregnant women). cnbc.com/2020/12/12/cdc…
But who was excluded from phase 3 trial? Many groups!
Pregnant/breastfeeding women
History of anaphylaxis
Immunocompromised
Those being treated w/ corticosteriods
etc.
What wildlife could be reservoirs for SARS-CoV-2?
New paper suggests North American big brown bats are not. Here's why this is important & why we need more studies like this.
Thread onlinelibrary.wiley.com/doi/10.1111/tb…
We still don't know the natural reservoir for SARS-CoV-2. Some similar viruses were found in horseshoe bats (Rhinolophus spp.), but the difference between those viruses & SARS-CoV-2 is large enough that SARS-CoV-2 may have different reservoir. ncbi.nlm.nih.gov/pmc/articles/P…
Regardless of where SARS-CoV-2 originally came from, many have worried that SARS-CoV-2 might be transmitted from humans into other animals that might be able to sustain the virus & transmit it back to humans.